EUCTR2013-003194-10-IT进行中（未招募）1 期
A Phase II Single Arm Trial Evaluating the Efficacy and Safety of Eribulin in Combination With Bevacizumab for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Progressing after First-Line Therapy With Bevacizumab and Paclitaxel - GIM11-BERGI
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 61
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •1.Signed informed consent
- •2.Female patients =18 years of age.
- •3.Histologically confirmed HER2-negative adenocarcinoma of the breast with documented progression of disease per investigator assessment following or during first-line treatment with Bevacizumab in combination with Paclitaxel for MBC; patients can have measurable or non-measurable disease;
- •4.A minimum of 4 cycles of Bevacizumab 15 mg/kg or 6 cycles 10 mg/kg received in the first-line setting.
- •5.Patients must have received Bevacizumab in combination with Paclitaxel.
- •6.ECOG performance status (PS) of 0-2.
- •7.At least 28 days since prior radiation therapy or surgery and recovery from treatment.
- •8.Patients must have measurable disease which must be evaluable per RECIST v1.1.
- •9. Estimated life expectancy of =12 weeks
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 61
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 61
排除标准
- •1.Patients who have received anti-angiogenic therapy other than Bevacizumab for the first-line treatment of MBC.
- •2.Patients who have exclusively received endocrine treatment in combination with Bevacizumab until the first progression.
- •3.Positive or unknown HER2/neu status or for whom determination of HER2 status is not possible.
- •4.Current, recent (within 4 weeks or 2 half-lives, whichever is greater, before day 1) or planned participation in an experimental drug study - other than a Bevacizumab breast cancer study.
- •5.Active malignancy, other than superficial basal cell and superficial squamous (skin) cell, or carcinoma in situ of the cervix or breast within the last 5 years.
- •6.Any laboratory values at baseline as follows:
- •Hematology:
- •-ANC <1.5x109/L or 1500/mm3
- •-Platelet count <75x109/L
- •-Hemoglobin <8 g/dL (Note: hemoglobin levels may be supported by transfusion or erythropoietin or other approved hematopoietic growth factors).
- •Coagulation:
- •-INR >1.5 except for patients on stable anticoagulant therapy
- •-aPTT =1.5 times ULN or greater than the lower limit of the therapeutic range
- •Note: The use of full-dose oral or parenteral anticoagulants is permitted as long as the INR or aPTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose of anticoagulants for at least two weeks at the time of Day 1, Cycle 1.
- •Serum chemistry:
- •-Total bilirubin >1.5 volte ULN
- •-AST or ALT >2 volte ULN (>5 times ULN for patients with known liver involvement)
- •-ALP >2 times ULN (>5 times ULN for patients with known liver involvement and >7 times ULN for patients with known bone involvement).
- •7.Inadequate renal function, defined as:
- •a.Creatinine clearance <50 mL/min
- •b.Urine dipstick for proteinuria =2+ unless a 24-hour protein =1 g is demonstrated.
- •8.Psychiatric or addictive disorders
- •9.Serious active infection requiring i.v. antibiotics and/or hospitalization at study entry.
- •10. Patients who are treated with any medicinal product that contraindicates the use of any of the study drugs, may interfere with the planned treatment, affects patient compliance or puts the patient at high risk for treatment-related complications.
- •11. Bevacizumab-specific exclusions
- •12. Eribulina-specific exlusions
研究者
相似试验
进行中（未招募）
1 期
A Phase II Single Arm Trial Evaluating the Efficacy and Safety of Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas Progressing after First-Line Platinum- based TherapyEUCTR2016-005238-31-ITISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE25
进行中（未招募）
1 期
Osimertinib plus savolitinib in patients with EGFRm+/MET+ non small cell lung cancer following prior osimertinibEGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung CancerEUCTR2018-003012-51-ESAstraZeneca AB172
进行中（未招募）
1 期
Osimertinib plus savolitinib in patients with EGFRm+/MET+ non small cell lung cancer following prior osimertinibEGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer.MedDRA version: 21.1Level: PTClassification code: 10029515Term: Non-small cell lung cancer recurrent Class: 100000004864CTIS2024-512581-34-00AstraZeneca AB259
进行中（未招募）
1 期
Osimertinib plus savolitinib in patients with EGFRm+/MET+ non small cell lung cancer following prior osimertinibEGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003012-51-ITASTRAZENECA AB259
进行中（未招募）
1 期
A Study of Idelalisib in Combination with Rituximab for Previously Untreated Chronic Lymphocytic Leukemia with 17p DeletioChronic Lymphocytic Leukemia with 17p deletionMedDRA version: 18.1Level: LLTClassification code 10068919Term: B-cell chronic lymphocytic leukemiaSystem Organ Class: 100000004864EUCTR2013-003314-41-PTGilead Sciences, Inc.100